Pfizer Inc. (NYSE:PFE) Shares Acquired by America First Investment Advisors LLC

America First Investment Advisors LLC raised its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 5.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 650,254 shares of the biopharmaceutical company's stock after purchasing an additional 35,978 shares during the quarter. Pfizer accounts for about 4.2% of America First Investment Advisors LLC's holdings, making the stock its 17th biggest position. America First Investment Advisors LLC's holdings in Pfizer were worth $18,818,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Swiss National Bank lifted its position in shares of Pfizer by 0.6% during the 3rd quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company's stock valued at $486,762,000 after acquiring an additional 100,900 shares during the period. Empowered Funds LLC lifted its stake in shares of Pfizer by 80.9% during the 3rd quarter. Empowered Funds LLC now owns 508,256 shares of the biopharmaceutical company's stock worth $14,709,000 after purchasing an additional 227,349 shares during the period. Addison Advisors LLC grew its position in shares of Pfizer by 394.2% in the third quarter. Addison Advisors LLC now owns 52,238 shares of the biopharmaceutical company's stock valued at $1,512,000 after purchasing an additional 41,668 shares during the period. KBC Group NV increased its stake in Pfizer by 26.0% in the third quarter. KBC Group NV now owns 3,105,433 shares of the biopharmaceutical company's stock valued at $89,872,000 after purchasing an additional 639,985 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its position in Pfizer by 4.3% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 13,118,764 shares of the biopharmaceutical company's stock worth $379,657,000 after buying an additional 544,418 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction on Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This represents a 11.11 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.06% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. UBS Group increased their price objective on shares of Pfizer from $30.00 to $31.00 and gave the stock a "neutral" rating in a report on Wednesday, July 31st. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. StockNews.com lowered Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday. Daiwa America upgraded Pfizer from a "moderate buy" rating to a "strong-buy" rating in a report on Wednesday, August 7th. Finally, Evercore ISI upgraded shares of Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $32.92.

Pfizer Stock Up 0.8 %

NYSE:PFE traded up $0.19 on Thursday, reaching $25.13. The stock had a trading volume of 44,565,492 shares, compared to its average volume of 38,472,188. The company has a 50-day moving average of $28.36 and a 200 day moving average of $28.61. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market cap of $142.41 billion, a P/E ratio of 33.65, a price-to-earnings-growth ratio of 0.80 and a beta of 0.67. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. Pfizer's revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.17) earnings per share. On average, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.69%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer's dividend payout ratio is currently 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.